

Maria Trojano

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5425059/maria-trojano-publications-by-citations.pdf>

Version: 2024-04-16

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

387
papers

17,727
citations

66
h-index

118
g-index

427
ext. papers

21,678
ext. citations

5.3
avg, IF

6.06
L-index

#	Paper	IF	Citations
387	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology, The</i> , 2018 , 17, 162-173	24.1	2419
386	Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. <i>Neurology</i> , 2005 , 64, 1144-51	6.5	698
385	Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994 , 57, 897-902	5.5	443
384	The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 305-17	5	286
383	The RaoQ Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 787-93	5	273
382	The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. <i>Neurology</i> , 2004 , 63, 919-21	6.5	221
381	Clinical characteristics, course and prognosis of relapsing DevicQ Neuromyelitis Optica. <i>Journal of Neurology</i> , 2004 , 251, 47-52	5.5	214
380	Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. <i>Journal of Neurology</i> , 1997 , 244, 153-9	5.5	212
379	Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , 2008 , 70, 1891-7	6.5	209
378	New natural history of interferon-beta-treated relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2007 , 61, 300-6	9.4	208
377	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 263-81	5	203
376	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021 , 89, 780-789	9.4	189
375	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1013-24	5	181
374	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016 , 139, 2395-405	11.2	172
373	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 175-187	27.4	172
372	Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. <i>Neurology</i> , 2010 , 75, 1134-40	6.5	170
371	Multicenter Case-Control Study on Restless Legs Syndrome in Multiple Sclerosis: the REMS Study. <i>Sleep</i> , 2008 , 31, 944-952	1.1	156

370	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology, The</i> , 2018 , 17, 405-415	24.1	150
369	Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 779-88	5	141
368	Geographical variations in sex ratio trends over time in multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e48078	3.7	139
367	Age-related disability in multiple sclerosis. <i>Annals of Neurology</i> , 2002 , 51, 475-80	9.4	137
366	Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1258-1267	5	136
365	Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. <i>Journal of Neuroimmunology</i> , 2003 , 136, 46-53	3.5	134
364	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1190-7	5.5	130
363	Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. <i>Glia</i> , 2009 , 57, 1363-73	9	128
362	Treatment decisions in multiple sclerosis - insights from real-world observational studies. <i>Nature Reviews Neurology</i> , 2017 , 13, 105-118	15	126
361	Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. <i>Journal of Neurology</i> , 2006 , 253, 1054-9	5.5	123
360	Pregnancy and fetal outcomes after interferon- β exposure in multiple sclerosis. <i>Neurology</i> , 2010 , 75, 1794-802	6.5	121
359	MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 769-74	5	121
358	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015 , 77, 425-35	9.4	118
357	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016 , 80, 89-100	9.4	117
356	Breastfeeding is not related to postpartum relapses in multiple sclerosis. <i>Neurology</i> , 2011 , 77, 145-50	6.5	116
355	Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2004 , 251, 1208-14	5.5	114
354	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014 , 82, 1204-11	6.5	113
353	Changes of serum sICAM-1 and MMP-9 induced by rIFN β -1b treatment in relapsing-remitting MS. <i>Neurology</i> , 1999 , 53, 1402-8	6.5	111

352	Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2009 , 66, 513-20	9.4	109
351	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015 , 138, 3287-98	11.2	107
350	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 739-46	5	104
349	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017 , 140, 2776-2796	11.2	102
348	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , 2017 , 16, 271-281	24.1	101
347	Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 77-87	5	98
346	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013 , 136, 3609-17	11.2	96
345	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 318-31	5	92
344	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 282-93	5	91
343	Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 420-4	5	90
342	Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. <i>Multiple Sclerosis Journal</i> , 2002 , 8, 222-8	5	88
341	Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. <i>Investigative Ophthalmology and Visual Science</i> , 2005 , 46, 1264-8		86
340	Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995 , 58, 300-6	5.5	86
339	Anxiety and depression in multiple sclerosis patients around diagnosis. <i>Journal of the Neurological Sciences</i> , 2011 , 307, 86-91	3.2	85
338	Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. <i>JAMA Neurology</i> , 2015 , 72, 405-13	17.2	83
337	Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 91-8	5	81
336	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015 , 10, e0122686	3.7	80
335	Neuropsychological features in childhood and juvenile multiple sclerosis: five-year follow-up. <i>Neurology</i> , 2014 , 83, 1432-8	6.5	78

334	The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population. <i>BMC Neurology</i> , 2014 , 14, 171	3.1	78
333	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , 2020 , 19, 307-316	24.1	77
332	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 342-9	5	76
331	Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 68-77	5	75
330	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , 2019 , 18, 185-197	24.1	74
329	Assessing response to interferon- β in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016 , 87, 134-40	6.5	74
328	The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. <i>Journal of Neurology</i> , 2002 , 249, 152-63	5.5	74
327	Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. <i>BMC Neurology</i> , 2012 , 12, 124	3.1	72
326	Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 441-6	5	70
325	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010 , 352, 23-31	2.5	69
324	Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. <i>PLoS ONE</i> , 2012 , 7, e35843	3.7	68
323	Caregiver quality of life in multiple sclerosis: a multicentre Italian study. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 412-9	5	68
322	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 126-9	5.5	66
321	Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. <i>BMC Neurology</i> , 2012 , 12, 165	3.1	66
320	Communicating the diagnosis of multiple sclerosis - a qualitative study. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 763-9	5	66
319	Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 329-34	5	65
318	A genome screen for multiple sclerosis in Italian families. <i>Genes and Immunity</i> , 2001 , 2, 205-10	4.4	65
317	High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. <i>Journal of the Neurological Sciences</i> , 1996 , 144, 182-90	3.2	64

3 ¹⁶	Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. <i>Brain</i> , 2015 , 138, 3275-86	11.2	63
3 ¹⁵	Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 944-51	5.5	63
3 ¹⁴	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017 , 140, 2426-2443	11.2	62
3 ¹³	Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 451-7	5	60
3 ¹²	Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Acta Neuropathologica Communications</i> , 2014 , 2, 84	7.3	59
3 ¹¹	Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. <i>Neurology</i> , 2011 , 77, 1887-95	6.5	59
3 ¹⁰	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 590-603	5	58
3 ⁰⁹	An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 1393-405	5	58
3 ⁰⁸	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. <i>Neurological Sciences</i> , 2009 , 30, 193-9	3.5	58
3 ⁰⁷	Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 1225-33	5	58
3 ⁰⁶	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 294-304	5	57
3 ⁰⁵	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1133-7	5.5	57
3 ⁰⁴	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014 , 76, 880-90	9.4	57
3 ⁰³	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018 , 90, e823-e831	6.5	54
3 ⁰²	Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. <i>Journal of Neuroimmunology</i> , 2005 , 163, 172-8	3.5	54
3 ⁰¹	Pregnancy, sex and hormonal factors in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 527-36	5	52
3 ⁰⁰	Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding. <i>Journal of Biological Chemistry</i> , 2011 , 286, 9216-24	5.4	52
2 ⁹⁹	Post-receptorial mechanisms underlie functional dysregulation of beta2-adrenergic receptors in lymphocytes from Multiple Sclerosis patients. <i>Journal of Neuroimmunology</i> , 2004 , 155, 143-9	3.5	52

298	Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. <i>Sleep</i> , 2008 , 31, 944-52	1.1	52
297	Recommendations for observational studies of comorbidity in multiple sclerosis. <i>Neurology</i> , 2016 , 86, 1446-1453	6.5	51
296	Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1106-12	5	50
295	Quality assurance for cerebrospinal fluid protein analysis: international consensus by an Internet-based group discussion. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003 , 41, 331-7	5.9	50
294	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1511-22	5	49
293	Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. <i>Neurological Sciences</i> , 2007 , 28, 127-32	3.5	49
292	Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. <i>Neurology</i> , 2018 , 90, e832-e839	6.5	48
291	Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 845-50	5.5	48
290	Acute changes in blood-CSF barrier permselectivity to serum proteins after intrathecal methotrexate and CNS irradiation. <i>Journal of Neurology</i> , 1985 , 231, 336-9	5.5	48
289	Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 757-9	5.5	47
288	Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. <i>Journal of Interferon and Cytokine Research</i> , 2005 , 25, 395-406	3.5	46
287	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 458-468	5.5	46
286	Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. <i>Human Molecular Genetics</i> , 2018 , 27, 66-79	5.6	45
285	Age at onset in multiple sclerosis. <i>Neurological Sciences</i> , 2000 , 21, S825-9	3.5	45
284	Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). <i>JAMA Neurology</i> , 2014 , 71, 954-60	17.2	44
283	Cerebral cortex demyelination and oligodendrocyte precursor response to experimental autoimmune encephalomyelitis. <i>Neurobiology of Disease</i> , 2011 , 43, 678-89	7.5	44
282	The brief neuropsychological battery for children: a screening tool for cognitive impairment in childhood and juvenile multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 620-6	5	44
281	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1343-1349	5.5	44

280	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 196-203	5.5	43
279	Multiple sclerosis registries in Europe - results of a systematic survey. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1523-32	5	43
278	The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. <i>Neurological Sciences</i> , 2001 , 22 Suppl 2, S98-102	3.5	43
277	Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport. <i>Glia</i> , 2017 , 65, 790-803	9	42
276	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 963-973 ⁵		42
275	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 373-87	5.3	42
274	Subcutaneous interferon β 1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. <i>PLoS ONE</i> , 2013 , 8, e74111 ^{3,7}		42
273	Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2005 , 239, 95-9	3.2	42
272	A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. <i>Canadian Journal of Neurological Sciences</i> , 1994 , 21, 266-70	1	42
271	The Italian multiple sclerosis register. <i>Neurological Sciences</i> , 2019 , 40, 155-165	3.5	42
270	Glatiramer acetate in multiple sclerosis: a review. <i>CNS Neuroscience & Therapeutics</i> , 2007 , 13, 178-91		41
269	Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patients. <i>Annals of Neurology</i> , 2003 , 54, 119-22	9.4	41
268	Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients. <i>Neurological Sciences</i> , 2013 , 34, 2085-93	3.5	40
267	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 974-82	5	40
266	Natalizumab discontinuation and disease restart in pregnancy: a case series. <i>Acta Neurologica Scandinavica</i> , 2015 , 131, 336-40	3.8	39
265	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 660-668	5.5	39
264	Anxiety state affects information processing speed in patients with multiple sclerosis. <i>Neurological Sciences</i> , 2014 , 35, 559-63	3.5	39
263	Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 991-1001	5	39

262	Intrathecal IgG synthesis in multiple sclerosis: comparison between isoelectric focusing and quantitative estimation of cerebrospinal fluid IgG. <i>Journal of Neurology</i> , 1981 , 224, 159-69	5.5	39
261	The impact of neutralizing antibodies on the risk of disease worsening in interferon β -treated relapsing multiple sclerosis: a 5-year post-marketing study. <i>Journal of Neurology</i> , 2013 , 260, 1562-8	5.5	38
260	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 100-11	5	38
259	observational studies: propensity score analysis of non-randomized data. <i>International MS Journal</i> , 2009 , 16, 90-7		38
258	Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon- β therapy. <i>NeuroImmunoModulation</i> , 2012 , 19, 283-92	2.5	37
257	Immunomodulatory therapies delay disease progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1732-1740	5	36
256	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 479-91	5.3	36
255	Psychosocial issue in children and adolescents with multiple sclerosis. <i>Neurological Sciences</i> , 2010 , 31, 467-70	3.5	36
254	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1738-1744	5.3	36
253	Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1508-17	5	35
252	ICAM 1 expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon beta-1a and TNFalpha. <i>Journal of Neuroimmunology</i> , 1998 , 88, 13-20	3.5	35
251	Variations of the perforin gene in patients with multiple sclerosis. <i>Genes and Immunity</i> , 2008 , 9, 438-44	4.4	35
250	European validation of a standardized clinical description of multiple sclerosis. <i>Journal of Neurology</i> , 2004 , 251, 1472-80	5.5	35
249	Apolipoprotein E genotype does not influence the progression of multiple sclerosis. <i>Journal of Neurology</i> , 2003 , 250, 1094-8	5.5	35
248	Investigating the Effects of COVID-19 Quarantine in Migraine: An Observational Cross-Sectional Study From the Italian National Headache Registry (RiCe). <i>Frontiers in Neurology</i> , 2020 , 11, 597881	4.1	35
247	Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. <i>Neurology</i> , 1996 , 47, 1535-41	6.5	34
246	Linkage analysis of multiple sclerosis with candidate region markers in Sardinian and Continental Italian families. <i>European Journal of Human Genetics</i> , 1999 , 7, 377-85	5.3	34
245	Multiple sclerosis registries in Europe - An updated mapping survey. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 171-178	4	33

244	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 23-37	5	32
243	Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide. <i>Journal of the Neurological Sciences</i> , 2020 , 416, 117011	3.2	31
242	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017 , 89, 1050-1059	6.5	31
241	Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. <i>Human Immunology</i> , 2003 , 64, 274-84	2.3	31
240	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 520-32	5	30
239	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 332-41 ⁵		30
238	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1159-71	5	30
237	The challenge of comorbidity in clinical trials for multiple sclerosis. <i>Neurology</i> , 2016 , 86, 1437-1445	6.5	30
236	Elevated plasma homocysteine levels in patients with multiple sclerosis are associated with male gender. <i>Journal of Neurology</i> , 2012 , 259, 2105-10	5.5	30
235	Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?. <i>Neurologic Clinics</i> , 2011 , 29, 309-21	4.5	30
234	Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta. <i>Brain Research Bulletin</i> , 2003 , 61, 357-64	3.9	30
233	The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. <i>Brain, Behavior, and Immunity</i> , 2014 , 35, 176-81	16.6	29
232	Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. <i>PLoS ONE</i> , 2013 , 8, e79185	3.7	29
231	Multiple sclerosis in Italy: cost-of-illness study. <i>Neurological Sciences</i> , 2011 , 32, 787-94	3.5	29
230	Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. <i>PLoS ONE</i> , 2012 , 7, e38661	3.7	29
229	Guidelines on the clinical use for the detection of neutralizing antibodies (NABs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. <i>Neurological Sciences</i> , 2014 , 35, 307-16	3.5	28
228	The coexistence of well- and ill-being in persons with multiple sclerosis, their caregivers and health professionals. <i>Journal of the Neurological Sciences</i> , 2014 , 337, 67-73	3.2	28
227	A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients. <i>BMC Neurology</i> , 2015 , 15, 204	3.1	28

226	Safety profile of Tysabri: international risk management plan. <i>Neurological Sciences</i> , 2009 , 30 Suppl 2, S159-62	3.5	28
225	Multigate quality Doppler profiles and morphological/hemodynamic alterations in multiple sclerosis patients. <i>Current Neurovascular Research</i> , 2012 , 9, 120-7	1.8	28
224	Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers. <i>Journal of Clinical Psychology in Medical Settings</i> , 2016 , 23, 33-52	2	27
223	Overexpression of autophagic proteins in the skeletal muscle of sporadic inclusion body myositis. <i>Neuropathology and Applied Neurobiology</i> , 2013 , 39, 736-49	5.2	27
222	Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. <i>PLoS ONE</i> , 2014 , 9, e103984	3.7	27
221	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012 , 318, 94-9	3.2	27
220	The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 305-10	5.5	27
219	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. <i>Biologics: Targets and Therapy</i> , 2009 , 3, 369-76	4.4	27
218	Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. <i>European Neurology</i> , 2016 , 76, 216-226	2.1	27
217	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 79-90	5	27
216	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017 , 81, 729-739	9.4	26
215	AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 51	7.3	26
214	The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 578-85	5	26
213	Disease Modifying Therapies and COVID-19 Severity in Multiple Sclerosis. <i>SSRN Electronic Journal</i> ,	1	26
212	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. <i>Journal of Neurology</i> , 2021 , 268, 3961-3968	5.5	26
211	Investigating the Role of MicroRNA and Transcription Factor Co-regulatory Networks in Multiple Sclerosis Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	25
210	Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012 , 245, 93-7	3.5	24
209	Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. <i>Journal of Neurology</i> , 2007 , 254, 597-604	5.5	24

208	CD45 and multiple sclerosis: the exon 4 C77G polymorphism (additional studies and meta-analysis) and new markers. <i>Journal of Neuroimmunology</i> , 2003 , 140, 216-21	3.5	24
207	BREMSO: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , 2015 , 22, 981-9	6	23
206	Age-related changes of serum N-acetyl-aspartate in healthy controls. <i>Age and Ageing</i> , 2011 , 40, 391-5	3	23
205	Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients. <i>Journal of Neuroimmunology</i> , 2008 , 197, 140-6	3.5	23
204	A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. <i>Journal of the Neurological Sciences</i> , 2004 , 223, 69-71	3.2	23
203	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 266-276	5	22
202	Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. <i>BMC Neurology</i> , 2014 , 14, 114	3.1	22
201	Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e63480	3.7	22
200	Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. <i>Journal of the Neurological Sciences</i> , 2009 , 286, 109-13	3.2	22
199	Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. <i>Journal of Neuroimmunology</i> , 2006 , 179, 108-16	3.5	22
198	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 28, 235-243	4	22
197	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1617-1626	5	21
196	The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. <i>Neurological Sciences</i> , 2003 , 24 Suppl 5, S268-70	3.5	21
195	Comparative efficacy of first-line natalizumab vs IFN- β or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016 , 6, 102-115	1.7	21
194	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211035318	5	21
193	Interferon beta-1a counteracts effects of activation on the expression of G-protein-coupled receptor kinases 2 and 3, beta-arrestin-1, and regulators of G-protein signalling 2 and 16 in human mononuclear leukocytes. <i>Cellular Signalling</i> , 2002 , 14, 673-8	4.9	20
192	Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. <i>Brain</i> , 2020 , 143, 3013-3024	11.2	20
191	Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice. <i>PLoS ONE</i> , 2019 , 14, e0213508	3.7	19

190	Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study. <i>Journal of Clinical Pharmacology</i> , 2015 , 55, 1131-6	2.9	19
189	The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1741-1749	5	19
188	Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach. <i>Neurological Sciences</i> , 2017 , 38, 1849-1858	3.5	19
187	Low serum urate levels are associated to female gender in multiple sclerosis patients. <i>PLoS ONE</i> , 2012 , 7, e40608	3.7	19
186	A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. <i>Genes and Immunity</i> , 2008 , 9, 7-15	4.4	19
185	Atypical forms of multiple sclerosis or different phases of a same disease?. <i>Neurological Sciences</i> , 2004 , 25 Suppl 4, S323-5	3.5	19
184	IFN-beta1a modulates the expression of CTLA-4 and CD28 splice variants in human mononuclear cells: induction of soluble isoforms. <i>Journal of Interferon and Cytokine Research</i> , 2001 , 21, 809-12	3.5	19
183	Heterogeneous models for blood-cerebrospinal fluid barrier permeability to serum proteins in normal and abnormal cerebrospinal fluid/serum protein concentration gradients. <i>Journal of the Neurological Sciences</i> , 1984 , 64, 245-58	3.2	19
182	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. <i>European Journal of Neurology</i> , 2016 , 23, 729-36	6	19
181	Guillain-Barré syndrome after AstraZeneca COVID-19-vaccination: A causal or casual association?. <i>Clinical Neurology and Neurosurgery</i> , 2021 , 208, 106887	2	19
180	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 642-652	5	18
179	No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β therapy in relapsing-remitting multiple sclerosis (the ARIANNA study). <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1163-73 ⁵		18
178	Inhibition of protein kinase C counteracts TNF α -induced intercellular adhesion molecule 1 expression and fluid phase endocytosis on brain microvascular endothelial cells. <i>Brain Research</i> , 2000 , 863, 245-8	3.7	18
177	Soluble intercellular adhesion molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system. <i>Multiple Sclerosis Journal</i> , 1998 , 4, 39-44	5	18
176	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021 , 96, e783-e797	6.5	18
175	Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients. <i>Journal of Neurology</i> , 2016 , 263, 1620-5	5.5	17
174	Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1153-60 ⁵		17
173	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 1355-9	5.5	17

172	Association between Synapsin III gene promoter polymorphisms and multiple sclerosis. <i>Journal of Neurology</i> , 2004 , 251, 165-70	5.5	17
171	Italian studies on early-onset multiple sclerosis: the present and the future. <i>Neurological Sciences</i> , 2004 , 25 Suppl 4, S346-9	3.5	17
170	Differential regulation of membrane bound and soluble ICAM 1 in human endothelium and blood mononuclear cells: effects of interferon beta-1a. <i>Cell Communication and Adhesion</i> , 2002 , 9, 259-72		17
169	COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	17
168	A Pattern of Cognitive Deficits Stratified for Genetic and Environmental Risk Reliably Classifies Patients With Schizophrenia From Healthy Control Subjects. <i>Biological Psychiatry</i> , 2020 , 87, 697-707	7.9	17
167	Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort. <i>Brain and Behavior</i> , 2017 , 7, e00804	3.4	16
166	Autophagy markers LC3 and p62 accumulate in immune-mediated necrotizing myopathy. <i>Muscle and Nerve</i> , 2019 , 60, 315-327	3.4	16
165	Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2013 , 330, 56-60	3.2	16
164	Serum levels of N-acetyl-aspartate in migraine and tension-type headache. <i>Journal of Headache and Pain</i> , 2012 , 13, 389-94	8.8	16
163	A whole genome screen for linkage disequilibrium in multiple sclerosis performed in a continental Italian population. <i>Journal of Neuroimmunology</i> , 2003 , 143, 97-100	3.5	16
162	Interferon beta-1a downregulates TNFalpha-induced intercellular adhesion molecule 1 expression on brain microvascular endothelial cells through a tyrosine kinase-dependent pathway. <i>Brain Research</i> , 2000 , 881, 227-30	3.7	16
161	The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 18-33	5	16
160	Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 396-401	5	15
159	Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1039-1045	5	15
158	Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study. <i>European Neurology</i> , 2015 , 74, 178-85	2.1	15
157	Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society. <i>Neurological Sciences</i> , 2011 , 32, 351-8	3.5	15
156	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101868	4	15
155	Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study. <i>Brain and Behavior</i> , 2019 , 9, e01199	3.4	14

154	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369	5	14
153	Treating multiple sclerosis with natalizumab. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1683-92	4.3	14
152	Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients. <i>Journal of Neurology</i> , 2006 , 253, 231-6	5.5	14
151	Italian Multiple Sclerosis Database Network. <i>Neurological Sciences</i> , 2006 , 27 Suppl 5, S358-61	3.5	14
150	Serum IgG to brain microvascular endothelial cells in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1996 , 143, 107-13	3.2	14
149	Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients. <i>Journal of Neuroimmunology</i> , 2017 , 303, 75-80	3.5	13
148	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020 , 143, 1400-1413	11.2	13
147	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018 , 75, 1407-1415	17.2	13
146	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1346-1357	5	13
145	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 1297-1303	5.5	13
144	History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort. <i>Neurology</i> , 2016 , 87, 1360-7	6.5	13
143	Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 845-51	2.9	12
142	Implementation of the Capere MiglioraQnformation aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1234-43	5	12
141	Illness perceptions and psychological adjustment among persons with multiple sclerosis: the mediating role of coping strategies and social support. <i>Disability and Rehabilitation</i> , 2020 , 42, 3780-3792 ^{2.4}	2.4	12
140	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 24, 11-19	4	12
139	Supramolecular aggregation of aquaporin-4 is different in muscle and brain: correlation with tissue susceptibility in neuromyelitis optica. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 1236-1246	5.6	11
138	Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420922685	6.6	11
137	Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. <i>Expert Opinion on Drug Delivery</i> , 2016 , 13, 799-805	8	11

136	Lack of information about multiple sclerosis in children can impact parents' sense of competency and satisfaction within the couple. <i>Journal of the Neurological Sciences</i> , 2013 , 324, 100-5	3.2	11
135	Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β 1a in the COGNITIVE Impairment in Multiple Sclerosis (COGIMUS) study. <i>BMC Neurology</i> , 2011 , 11, 125	3.1	11
134	Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003 , 143, 31-8	3.5	11
133	Serum soluble intercellular adhesion molecule-I in MS: relation to clinical and Gd-MRI activity and to rIFN beta-1b treatment. <i>Multiple Sclerosis Journal</i> , 1998 , 4, 183-7	5	11
132	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018 , 391, 72-76	3.2	11
131	Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study. <i>Therapeutic Advances in Neurological Disorders</i> , 2009 , 2, 67-77	6.6	10
130	Comparison of clinical and demographic features between affected pairs of Italian multiple sclerosis multiplex families; relation to tumour necrosis factor genomic polymorphisms. <i>Journal of the Neurological Sciences</i> , 1999 , 162, 194-200	3.2	10
129	Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. <i>CNS Drugs</i> , 2020 , 34, 65-92	6.7	10
128	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1543-1555	5	10
127	Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort. <i>Frontiers in Immunology</i> , 2019 , 10, 1343	8.4	9
126	A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis. <i>Therapeutic Apheresis and Dialysis</i> , 2008 , 12, 250-4	1.9	9
125	Isoelectric focusing and quantitative estimation of cerebrospinal fluid and serum IgG in idiopathic polyneuropathy. <i>Journal of Neurology</i> , 1980 , 223, 1-12	5.5	9
124	Italian consensus on treatment of spasticity in multiple sclerosis. <i>European Journal of Neurology</i> , 2020 , 27, 445-453	6	9
123	The caring experience in multiple sclerosis: Caregiving tasks, coping strategies and psychological well-being. <i>Health and Social Care in the Community</i> , 2020 , 28, 236-246	2.6	9
122	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 591-600	5	9
121	The Contribution of Illness Beliefs, Coping Strategies, and Social Support to Perceived Physical Health and Fatigue in Multiple Sclerosis. <i>Journal of Clinical Psychology in Medical Settings</i> , 2021 , 28, 149-160	6.6	9
120	Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211019574	6.6	9
119	The heritage of glatiramer acetate and its use in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016 , 1,	0	8

118	Emotional and neutral verbal memory impairment in Multiple Sclerosis. <i>Journal of the Neurological Sciences</i> , 2014 , 341, 28-31	3.2	8
117	Fluctuations of MS births and UV-light exposure. <i>Acta Neurologica Scandinavica</i> , 2013 , 127, 301-8	3.8	8
116	Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. <i>Neurology</i> , 2013 , 81, 1470-1	6.5	8
115	Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system. <i>Multiple Sclerosis Journal</i> , 1998 , 4, 39-44	5	8
114	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020 , 77, 1398-1407	17.2	8
113	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020 , 143, 2742-2756	11.2	8
112	A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2240-2253	5	8
111	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019 , 26, 363-370	6	8
110	Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients. <i>European Cytokine Network</i> , 2003 , 14, 154-7	3.3	8
109	Tissue Distribution of the Readthrough Isoform of AQP4 Reveals a Dual Role of AQP4ex Limited to CNS. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
108	Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. <i>BMJ Open</i> , 2017 , 7, e017254	3	7
107	Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β 1a: results from the COGIMUS (COGNitive Impairment in Multiple Sclerosis) study (II). <i>Quality of Life Research</i> , 2012 , 21, 1111-21	3.7	7
106	Isoelectric focusing and crossed immunoelectrofocusing of cerebrospinal fluid proteins in neurological disorders. <i>Acta Neurologica</i> , 1978 , 33, 501-17		7
105	First evidence of in vivo pro-angiogenic activity of cerebrospinal fluid samples from multiple sclerosis patients. <i>Clinical and Experimental Medicine</i> , 2016 , 16, 103-7	4.9	6
104	Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. <i>Neurological Sciences</i> , 2020 , 41, 3185-3193	3.5	6
103	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595	5	6
102	Immunomodulatory properties of increased levels of liver X receptor beta in peripheral blood mononuclear cells from multiple sclerosis patients. <i>Experimental Neurology</i> , 2007 , 204, 759-66	5.7	6
101	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021 , 18, 905-919	6.4	6

100	PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels. <i>Biomedicines</i> , 2020 , 8,	4.8	5
99	Multiple sclerosis in 2017: Progress in multiple sclerosis - from diagnosis to therapy. <i>Nature Reviews Neurology</i> , 2018 , 14, 72-74	15	5
98	The role of neutralizing antibodies to interferon- β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1025-9	2.8	5
97	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015 , 1, 2055217315600193	2.3	5
96	Age-related vascular differences among patients suffering from multiple sclerosis. <i>Current Neurovascular Research</i> , 2014 , 11, 23-30	1.8	5
95	Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: a comparison of assay results from three italian centres. <i>Journal of Immunoassay and Immunochemistry</i> , 2009 , 30, 40-50	1.8	5
94	LFA-1 expression on CD4(+)CD45RO(+) peripheral blood T-lymphocytes in RR MS: effects induced by rIFNbeta-1a. <i>Journal of the Neurological Sciences</i> , 2001 , 186, 65-73	3.2	5
93	Mitochondria, Oxidative Stress, cAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceuticals. <i>Antioxidants</i> , 2020 , 10,	7.1	5
92	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). <i>PLoS ONE</i> , 2016 , 11, e0144834	3.7	5
91	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri Observational Program (TOP). <i>Multiple Sclerosis Journal</i> , 2021 , 27, 410-419	5	5
90	Gender Inequities in the Multiple Sclerosis Community: A Call for Action. <i>Annals of Neurology</i> , 2018 , 84, 958-959	9.4	5
89	First-line therapies in late-onset multiple sclerosis: An Italian registry study. <i>European Journal of Neurology</i> , 2021 , 28, 4117-4123	6	5
88	DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient. <i>Stem Cell Research and Therapy</i> , 2019 , 10, 29	8.3	4
87	Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study. <i>Neurological Sciences</i> , 2020 , 41, 2843-2851	3.5	4
86	Serum levels of N-acetylaspartate in Huntington@ disease: preliminary results. <i>Movement Disorders</i> , 2012 , 27, 329-30	7	4
85	Development of an Aquaporin-4 Orthogonal Array of Particle-Based ELISA for Neuromyelitis Optica Autoantibodies Detection. <i>PLoS ONE</i> , 2015 , 10, e0143679	3.7	4
84	The MoSt Project--more steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy. <i>Journal of Neurology</i> , 2014 , 261, 526-32	5.5	4
83	Can databasing optimise patient care?. <i>Journal of Neurology</i> , 2004 , 251 Suppl 5, v79-v82	5.5	4

82	Adrenergic mechanisms in multiple sclerosis: the neuro-immune connection?. <i>Trends in Pharmacological Sciences</i> , 2004 , 25, 350-1; author reply 351-2	13.2	4
81	The IFNbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy. <i>Neurological Sciences</i> , 2005 , 26 Suppl 4, S179-82	3.5	4
80	Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	4
79	The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy. <i>PLoS ONE</i> , 2016 , 11, e0159214	3.7	4
78	Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. <i>Journal of Neurology</i> , 2021 , 1	5.5	4
77	Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method. <i>Frontiers in Neurology</i> , 2021 , 12, 633115	4.1	4
76	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. <i>Journal of Headache and Pain</i> , 2019 , 20, 15	8.8	4
75	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 695-705	5	4
74	Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 719-728	5	4
73	Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. <i>European Journal of Neurology</i> , 2021 , 28, 567-578	6	4
72	Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1458-1463	5	3
71	Natalizumab reduces serum pro-angiogenic activity in MS patients. <i>Neurological Sciences</i> , 2018 , 39, 725-734	3.4	3
70	Cognitive and psychosocial features of childhood and juvenile MS. <i>Neurology</i> , 2009 , 72, 1189; author reply1189-90	6.5	3
69	Epstein-Barr virus (EBV) and multiple sclerosis association: EBV has a primary or secondary role?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009 , 80, 469	5.5	3
68	Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. <i>Biologics: Targets and Therapy</i> , 2009 , 369	4.4	3
67	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. <i>PLoS ONE</i> , 2016 , 11, e0157721	3.7	3
66	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. <i>Frontiers in Neurology</i> , 2021 , 12, 647811	4.1	3
65	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 755-766	5	3

64	Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus. <i>Journal of Neurology</i> , 2021 , 268, 1540-1543	5.5	3
63	Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1569-1577	5	3
62	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103012	4	3
61	MS and related disorders: looking for markers of phenotypes. <i>Lancet Neurology</i> , 2015 , 14, 11-3	24.1	2
60	Cognitive dysfunction in pediatric-onset multiple sclerosis	134-143	2
59	The challenge of demonstrating long-term benefit of disease-modifying therapies in multiple sclerosis	244-252	2
58	EXPOSURE TO INTERFERON- β THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, A17.2-A17	5.5	2
57	Postmarketing evidence of disease-modifying drugs in multiple sclerosis. <i>Neurological Sciences</i> , 2008 , 29 Suppl 2, S225-6	3.5	2
56	Comparing natural history of early and late onset pediatric multiple sclerosis.. <i>Annals of Neurology</i> , 2022 ,	9.4	2
55	Serum soluble intercellular adhesion molecule-1 in MS: relation to clinical and Gd-MRI activity and to rituximab treatment. <i>Multiple Sclerosis Journal</i> , 1998 , 4, 183-187	5	2
54	Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a. <i>Neurology</i> , 2021 , 96, e214-e227	6.5	2
53	Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1352-1357	5	2
52	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 479-482	5	2
51	A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review. <i>Brain and Behavior</i> , 2021 , 11, e01930	3.4	2
50	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1838-1851	5	2
49	A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis. <i>Scandinavian Journal of Rheumatology</i> , 2018 , 47, 336-337	1.9	2
48	Job satisfaction among physicians and nurses involved in the management of multiple sclerosis: the role of happiness and meaning at work. <i>Neurological Sciences</i> , 2021 , 1	3.5	2
47	Dengue fever in a multiple sclerosis patient taking Ocrelizumab. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2116-2118	2	2

46	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021 , 208, 106180	6.9	2
45	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211042458	6.6	2
44	Alteration of the translational readthrough isoform AQP4ex induces redistribution and downregulation of AQP4 in human glioblastoma.. <i>Cellular and Molecular Life Sciences</i> , 2022 , 79, 140	10.3	2
43	Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. <i>Journal of Neurology</i> ,	5.5	2
42	Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register. <i>Journal of Neurology</i> , 2019 , 266, 3098-3107	5.5	1
41	Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies. <i>Cells</i> , 2019 , 8,	7.9	1
40	Advances in the management of MS symptoms: real-life evidence. <i>Neurodegenerative Disease Management</i> , 2015 , 5, 19-21	2.8	1
39	Improving combination trials for multiple sclerosis. <i>Lancet Neurology, The</i> , 2010 , 9, 646-7	24.1	1
38	Blood-cerebrospinal fluid barrier permeability to serum IgG subfractions and measurement of intrathecal IgG synthesis. <i>Journal of the Neurological Sciences</i> , 1986 , 73, 325-38	3.2	1
37	The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2021 ,	6	1
36	Perampanel during pregnancy: Description of four cases. <i>Epilepsy and Behavior Reports</i> , 2021 , 16, 100490.	3	1
35	Early clinical markers of aggressive multiple sclerosis		1
34	Immunotherapy prevents long-term disability in relapsing multiple sclerosis over 15 years		1
33	A Pilot Longitudinal Evaluation of MicroRNAs for Monitoring the Cognitive Impairment in Pediatric Multiple Sclerosis. <i>Applied Sciences (Switzerland)</i> , 2020 , 10, 8274	2.6	1
32	Effect of Cladribine on Neuronal Apoptosis: New Insight of In Vitro Study in Multiple Sclerosis Therapy. <i>Brain Sciences</i> , 2020 , 10,	3.4	1
31	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. <i>Journal of Medical Internet Research</i> , 2021 , 23, e29558	7.6	1
30	Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. <i>Journal of Neurology</i> , 2021 , 1	5.5	1
29	THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms. <i>European Neurology</i> , 2016 , 75 Suppl 1, 4-8	2.1	1

28	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 430-438	5	1
27	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021 , 35, 1217-1232	6.7	1
26	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068	5	1
25	Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis.. <i>Frontiers in Neurology</i> , 2022 , 13, 787160	4.1	1
24	Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221079598	5	1
23	Durvalumab and multiple sclerosis: a causal link or simple unmasking?. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1773-1774	2.8	0
22	Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years. <i>Neurological Sciences</i> , 2021 , 42, 4647-4655	3.5	0
21	Environmental Factors and Their Regulation of Immunity in Multiple Sclerosis 2016 , 99-111		0
20	Assessing long-term effectiveness of MS treatment - a matter of debate. <i>Nature Reviews Neurology</i> , 2021 , 17, 197-198	15	0
19	Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review.. <i>Neurological Sciences</i> , 2022 , 1	3.5	0
18	Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset.. <i>Neurology</i> , 2022 , 98, e1626-e1636	6.5	0
17	Interdisciplinary approach to opportunistic infections: staphylococcal meningitis in a patient with multiple sclerosis on treatment with dimethyl fumarate.. <i>Internal and Emergency Medicine</i> , 2022 , 1	3.7	0
16	Italian validation of the caregiving tasks in multiple sclerosis scale (CTiMSS). <i>Neurological Sciences</i> , 2020 , 41, 1881-1889	3.5	
15	Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Foreword. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 1	4.3	
14	A rare case of multiple sclerosis and McArdle disease. <i>Neurological Sciences</i> , 2015 , 36, 1721-3	3.5	
13	Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?. <i>Neurology</i> , 2008 , 71, 463; author reply 463-4	6.5	
12	Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDIatric Italian Genetic and enviRonment ExposurE Questionnaire). <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211059048	2	
11	Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 58, 103484		4

- 10 Guillain-Barré Syndrome associated with inappropriate secretion of antidiuretic hormone following SARS-CoV-2 infection: A case-report. *Clinical Case Reports (discontinued)*, **2021**, 9, e04667 0.7
- 9 A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon- β 1a in multiple sclerosis patients. *Multiple Sclerosis and Related Disorders*, **2020**, 40, 101952 4
- 8 Intrathecal IgG Synthesis in Multiple Sclerosis: Correlation with Clinical Parameters **1988**, 21-31
- 7 Disease Duration, Relapse rate and Clinical Course in Multiple Sclerosis: Relation to IgG Production within the Blood Brain Barrier **1990**, 23-31
- 6 Magnetic resonance imaging, proton magnetic resonance spectroscopy and cerebrospinal fluid abnormalities in multiple sclerosis **1996**, 123-132
- 5 Blood-CSF barrier permselectivity and measurement of intrathecal IgG synthesis in multiple sclerosis **1984**, 441-447
- 4 Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study). *Frontiers in Neurology*, **2021**, 12, 637615 4.1
- 3 085 Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri observational program (TOP). *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**, 92, 1812-1814 5.5
- 2 Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.. *Pharmacoeconomics*, **2021**, 40, 323 4.4
- 1 023 Relapse outcomes with natalizumab Q4W vs switch to Q6W. *Journal of Neurology, Neurosurgery and Psychiatry*, **2022**, 93, A20.3-A21 5.5